drugset

drugset / Trial / NCT03422445

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

NCT03422445 ↗

Phase 2 Unknown 30 enrolled Peking University Cancer Hospital & Institute

NaSingle-groupOpen-labelTreatment

Summary

30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

Timeline

Start: 2018-01-08
Primary completion: 2019-02
Completion: 2019-02

Publications

Zhou L, Yang Y, Si L, Chi Z, Sheng X, Lian B, Wang X, Tang B, Mao L, Yan X, Li S, Bai X, Guo J, Cui C. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. Melanoma Res. 2022 Jun 1;32(3):142-149. doi: 10.1097/CMR.0000000000000809. Epub 2022 Feb 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	500 mg	Oral
Subject	Temozolomide	Small molecule	300 mg	Oral

Indications